Genomics Market - Global Industry Size, Share, Trends, Opportunity, and Forecast, Segmented By Products & Services (Systems & Software, Consumables, Service), By Technology (Sequencing, PCR, Nucleic Acid Extraction and Purification, Microarray, Others), By Application (Drug Discovery & Development, Diagnostics, Agriculture & Animal Research, Others), By End User (Hospitals & Clinics, Academic & Research Institutions, Biotechnology & Pharmaceutical Companies, Others), By Region and Competition, 2020-2030F

Market Overview

The Global Genomics Market was valued at USD 34.51 billion in 2024 and is expected to reach USD 94.36 billion by 2030 with a CAGR of 18.25% during the forecast period. The major factors include growing specialized medicines and wide application of genomics in numerous areas. Genomics is the branch of science that concerned with the structure, function, evolution, and mapping of genomes. Various steps are taken such as sampling, sequencing, data analysis and interpretation procedures to decode, assemble, and analyze genomes. Nowadays, people are diagnosed with genetic as well as chronic diseases due to which demand for personalized medicine is surging, which is bolstering the growth of the market. The other factors supporting the market's growth are advancement in diagnostic techniques, increasing investments by governments, surge in cancer incidents and rise in R&D initiatives.

Key Market Drivers

Declining Genome Sequencing Costs and Increasing Accessibility

One of the most transformative drivers of the global genomics market is the dramatic decline in genome sequencing costs, which has significantly widened accessibility for both research and clinical applications. According to the U.S. National Human Genome Research Institute (NHGRI), the cost of sequencing a human genome has fallen from nearly USD 100 million in 2001 during the Human Genome Project era to less than USD 600 by 2022.

This decline has outpaced even Moore’s Law in terms of technological cost reduction. Affordable sequencing enables large-scale applications such as population genomics projects, newborn screening pilots, and precision oncology diagnostics. Governments have leveraged this cost-effectiveness to launch massive cohort programs that were previously economically unfeasible. For example, national public health initiatives in North America, Europe, and Asia have invested heavily in genome sequencing programs for citizens, with the dual goals of building reference databases and integrating genomics into healthcare.

The reduced per-sample cost also supports more comprehensive studies in rare diseases, pharmacogenomics, and infectious disease surveillance. Lower sequencing costs translate directly into expanding market opportunities across consumables (flow cells, reagents), sequencing platforms, interpretation services, and bioinformatics software.

Government Investments and National Genomic Initiatives

Another crucial driver of the genomics market is the sustained investment by governments and the launch of national genomic initiatives aimed at integrating genomics into healthcare systems. Agencies such as the U.S. National Institutes of Health (NIH) and the National Human Genome Research Institute (NHGRI) allocate billions of dollars annually toward genomics research, infrastructure, and clinical adoption. Similarly, the UK’s National Health Service (NHS) established the Genomic Medicine Service, which is already delivering over 100,000 whole-genome tests per year to patients, making genomics a standard part of medical care. Public initiatives such as All of Us (U.S.), Genomics England (UK), and national sequencing programs in China and Japan are sequencing millions of participants to build diverse genomic and clinical datasets. These projects generate demand for sequencing instruments, data storage, and variant interpretation platforms while also providing the foundational evidence base for clinical adoption. Beyond research, public health agencies are embedding genomics into infectious disease surveillance — for example, genomic sequencing of pathogens was widely deployed during the COVID-19 pandemic to track variants. Government investment also supports workforce development, training genetic counselors, bioinformaticians, and clinical geneticists to ensure system readiness for large-scale adoption.

Download Free Sample Report

Key Market Challenges

Data Privacy, Security, and Public Trust in Genomic Information

The sensitive nature of genomic data presents a profound challenge to the global genomics market. Unlike routine health records, DNA data is inherently identifiable and contains predictive health information not just for the individual but also for their relatives. This amplifies privacy concerns and complicates governance. For instance, the U.S. Centers for Disease Control and Prevention (CDC) emphasizes strict standards for genomic data storage and access, while the European Union’s GDPR includes explicit protections for genetic data. National sequencing projects must balance the need for open research access with strict privacy controls. Technical challenges such as long-term secure storage, encrypted computation, and federated data analysis require significant investment and expertise. Public trust also plays a pivotal role: any breach or misuse of genomic data could lead to large-scale withdrawal from public projects, jeopardizing research continuity. Several countries have faced criticism for commercial partnerships involving public genomic databases, sparking debates over ethical governance.

Regulatory and Reimbursement Barriers to Clinical Integration

While genomics is revolutionizing research, translating it into everyday clinical care faces significant regulatory and reimbursement hurdles. Regulatory frameworks for genomic tests vary widely. In the United States, the Food and Drug Administration (FDA) regulates genetic tests differently depending on whether they are lab-developed or in vitro diagnostics, while in the EU, the In Vitro Diagnostic Regulation (IVDR) has imposed stricter evidence requirements for test approval. This regulatory diversity creates costly, time-consuming approval pathways for companies. Equally important, reimbursement policies remain inconsistent. Health insurers and public health systems often demand rigorous evidence of clinical utility before covering genomic tests. For example, while some pharmacogenomic tests are reimbursed in the U.S., many whole-genome sequencing tests are not fully covered, limiting patient access. National health systems like the UK’s NHS have started to reimburse large panels and whole-genome tests, but adoption is gradual and not uniform across conditions. Moreover, integrating genomics into healthcare requires training clinicians, embedding genomic reports into electronic health records, and updating clinical guidelines — all of which demand time and investment.

Key Market Trends

Expansion of Clinical Genomics and Precision Medicine

A defining trend is the rapid mainstreaming of genomic testing into standard clinical care. Oncology, rare disease diagnosis, and newborn screening are at the forefront. For instance, the UK NHS Genomic Medicine Service has integrated genomics into cancer care and rare disease diagnosis, delivering hundreds of thousands of tests annually. Similarly, the U.S. Centers for Disease Control and Prevention (CDC) supports genomic applications in newborn screening, identifying genetic risks early in life. Precision medicine initiatives globally are encouraging use of genomics to select targeted therapies, monitor treatment responses, and prevent adverse drug reactions through pharmacogenomics. The impact is visible in oncology, where genomic testing guides the prescription of targeted therapies like PARP inhibitors or immunotherapies. In rare diseases, rapid whole-genome sequencing has been shown to reduce diagnostic odysseys, saving healthcare costs while improving patient outcomes.

Growth of Large-Scale Public Genomic Datasets and AI-Driven Insights

Another major trend is the creation of large-scale genomic and clinical datasets, which serve as critical infrastructure for research and commercial innovation. National programs such as All of Us (U.S.), Genomics England (UK), and initiatives in Asia-Pacific countries are sequencing millions of individuals and linking genomic data with health records. These datasets provide diverse, longitudinal information that is invaluable for discovering disease associations, training artificial intelligence models, and developing precision therapies. Governments are increasingly making such resources available to researchers through secure, controlled-access platforms, fueling innovation in both academia and industry. AI and machine learning tools are now being applied to these datasets to improve variant interpretation, predict disease risks, and design next-generation diagnostics. This trend is also driving investments in cloud-based bioinformatics infrastructure, federated data analysis, and cybersecurity to handle the scale and sensitivity of information.

Segmental Insights

Products & Services Insights

Based on Products & Services, consumables account for the largest share of products and services, surpassing systems & software and services. Consumables include reagents, kits, assays, flow cells, and sample preparation products that are required for each sequencing or genomic analysis run. Unlike instruments or software, which are typically one-time or periodic capital expenditures, consumables are recurring purchases tied directly to the volume of genomic testing performed. Every genome sequenced or test performed requires multiple consumable inputs, making them a consistent and high-demand revenue stream for suppliers. For example, consumables are essential for workflows in next-generation sequencing (NGS), polymerase chain reaction (PCR), and microarray platforms. The U.S. National Human Genome Research Institute (NHGRI) data shows that the cost of consumables contributes the most significant portion of sequencing expenses, even as overall sequencing costs have declined sharply over the past decade.

Download Free Sample Report

Regional Insights

Based on the region, North America currently dominates the global genomics market, holding the largest share due to its advanced healthcare infrastructure, strong research ecosystem, and substantial government as well as private investments. The United States National Institutes of Health (NIH) remains the world’s largest public funder of biomedical research, with billions allocated annually to genomics through the National Human Genome Research Institute (NHGRI) and precision medicine initiatives. Programs like the All of Us Research Program, which aims to sequence over one million Americans, highlight the scale of U.S. government commitment. Additionally, the U.S. Food and Drug Administration (FDA) has established frameworks for regulating genomic and genetic tests, supporting faster clinical integration. Canada is also contributing significantly, with national genomics funding bodies like Genome Canada investing heavily in applied genomics research across healthcare, agriculture, and environment. According to Genome Canada, over CAD 3.5 billion has been invested in genomics since its inception, illustrating strong government support.

Recent Developments

• In January 2024, Gencove and Ferris Genomics announced the collaboration for end-to-end genomics sequencing services.
• In November 2023, Fabric Genomics collaborated with DNAnexus and Oxford Nanopore Technologies for deployment of CLIA/CAP labs in pediatric and neonatal ICU’s. The labs will use Oxford Nanopore’s platforms to study genetic disorders in infants.
• in February 2023, Illumina, Inc. entered a collaboration with African Centre of Excellence for Genomics of Infectious Diseases to start a training institute to increase genomic capabilities in African region
• In January 2023, SOPHiA GENETIC collaborated with the Memorial Sloan Kettering Cancer Center (MSK), a U.S. Cancer Center, to offer researchers and clinicians solutions to expand analytical and testing capabilities.

Key Market Players

• Illumina, Inc.
• Thermo Fischer Scientific, Inc.
• QIAGEN N.V.
• Agilent Technologies, Inc.
• F. Hoffmann-La Roche AG
• Bio-Rad Laboratories, Inc.
• Eurofins Scientific SE
• Oxford Nanopore Technologies Limited
• Pacific Biosciences of California, Inc.
• Danaher Corporation

Report Scope:

In this report, the Global Genomics Market has been segmented into the following categories, in addition to the industry trends which have also been detailed below:

• Genomics Market, By Products & Services:

o   Systems & Software

o   Consumables

o   Service

• Genomics Market, By Technology:

o   Sequencing

o   PCR

o   Nucleic Acid Extraction and Purification

o   Microarray

o   Others

• Genomics Market, By Application:

o   Drug Discovery & Development

o   Diagnostics

o   Agriculture & Animal Research

o   Others

• Genomics Market, By End User:

o   Hospitals & Clinics

o   Diagnostic Laboratories

o   Others

• Genomics Market, By Region:

o   North America

§  United States

§  Mexico

§  Canada

o   Europe

§  France

§  Germany

§  United Kingdom

§  Italy

§  Spain

o   Asia-Pacific

§  China

§  India

§  South Korea

§  Japan

§  Australia

o   South America

§  Brazil

§  Argentina

§  Colombia

o   Middle East and Africa

§  South Africa

§  Saudi Arabia

§  UAE

Competitive Landscape

Company Profiles: Detailed analysis of the major companies presents in the Global Genomics Market.

Available Customizations:

Global Genomics Market report with the given market data, TechSci Research offers customizations according to a company's specific needs. The following customization options are available for the report:

Company Information

• Detailed analysis and profiling of additional market players (up to five).

Global Genomics Market is an upcoming report to be released soon. If you wish an early delivery of this report or want to confirm the date of release, please contact us at [email protected]